DE69717281T2 - Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid - Google Patents

Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid

Info

Publication number
DE69717281T2
DE69717281T2 DE69717281T DE69717281T DE69717281T2 DE 69717281 T2 DE69717281 T2 DE 69717281T2 DE 69717281 T DE69717281 T DE 69717281T DE 69717281 T DE69717281 T DE 69717281T DE 69717281 T2 DE69717281 T2 DE 69717281T2
Authority
DE
Germany
Prior art keywords
phenylisoxazol
benzenesulfonamide
methyl
crystalline form
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69717281T
Other languages
English (en)
Other versions
DE69717281D1 (de
Inventor
J Talley
R Medich
T Mclaughlin
T Gaud
E Yonan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of DE69717281D1 publication Critical patent/DE69717281D1/de
Publication of DE69717281T2 publication Critical patent/DE69717281T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/40—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs
    • H01L23/4006—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs with bolts or screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/42—Fillings or auxiliary members in containers or encapsulations selected or arranged to facilitate heating or cooling
    • H01L23/427—Cooling by change of state, e.g. use of heat pipes
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/0001—Technical content checked by a classifier
    • H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Power Engineering (AREA)
  • Computer Hardware Design (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
DE69717281T 1996-08-14 1997-08-12 Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid Expired - Fee Related DE69717281T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2437896P 1996-08-14 1996-08-14
PCT/US1997/015126 WO1998006708A1 (en) 1996-08-14 1997-08-12 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide

Publications (2)

Publication Number Publication Date
DE69717281D1 DE69717281D1 (de) 2003-01-02
DE69717281T2 true DE69717281T2 (de) 2003-09-04

Family

ID=21820280

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69717281T Expired - Fee Related DE69717281T2 (de) 1996-08-14 1997-08-12 Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid

Country Status (39)

Country Link
US (2) US6441014B2 (de)
EP (2) EP0920422B1 (de)
JP (2) JP3631763B2 (de)
KR (1) KR100383148B1 (de)
CN (1) CN1205193C (de)
AP (1) AP1055A (de)
AR (1) AR009244A1 (de)
AT (1) ATE228117T1 (de)
AU (1) AU722072B2 (de)
BG (1) BG64259B1 (de)
BR (1) BR9711151A (de)
CA (1) CA2264104A1 (de)
CZ (1) CZ297679B6 (de)
DE (1) DE69717281T2 (de)
DK (1) DK0920422T3 (de)
EA (2) EA003754B1 (de)
EE (1) EE04237B1 (de)
ES (1) ES2188971T3 (de)
GE (1) GEP20022636B (de)
HK (1) HK1023125A1 (de)
HU (1) HUP0400923A3 (de)
IL (2) IL161224A0 (de)
IS (1) IS1989B (de)
LT (1) LT4551B (de)
LV (1) LV12274B (de)
NO (1) NO312461B1 (de)
NZ (1) NZ334132A (de)
OA (1) OA11298A (de)
PL (1) PL191313B1 (de)
PT (1) PT920422E (de)
RO (1) RO120771B1 (de)
RS (1) RS49671B (de)
SI (1) SI9720059B (de)
SK (1) SK283558B6 (de)
TR (1) TR199900298T2 (de)
TW (1) TW527350B (de)
UA (1) UA52684C2 (de)
WO (1) WO1998006708A1 (de)
ZA (1) ZA977314B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3631763B2 (ja) * 1996-08-14 2005-03-23 ジー・ディー・サール・アンド・カンパニー ４―［５―メチル―３―フェニルイソキサゾル―４―イル］ベンゼンスルホンアミドの結晶形
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
GB9810920D0 (en) * 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
AU5467699A (en) * 1998-08-07 2000-02-28 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
AU1398899A (en) * 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
CN1349423A (zh) * 1999-03-01 2002-05-15 奥索-麦克尼尔药品公司 包含曲马多物质和选择性cox－2抑制剂药物的组合物
SK286621B6 (sk) * 1999-08-20 2009-02-05 Ortho-Mcneil Pharmaceutical, Inc. Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva
EP1212051A4 (de) * 1999-08-27 2004-03-31 Merck & Co Inc Methode zur behandlung oder prävention von chemischer prostatitis oder chronischem beckenschmerz
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
ES2453164T3 (es) * 2001-08-15 2014-04-04 Pharmacia & Upjohn Company Llc Cristales que incluyen una sal de ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida, procedimientos para su preparación y sus composiciones
US20070072921A1 (en) * 2002-07-26 2007-03-29 Talley John J Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
AU2003238668A1 (en) 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
US20050182113A1 (en) * 2003-12-30 2005-08-18 Venkataraman Sundaram Method for preparing diaryl-substituted isoxazole compounds
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib
WO2005120499A1 (en) * 2004-06-10 2005-12-22 Chandiran Thakashinamoorthy Form a of valdecoxib suitable for pharmaceutical formulations
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
PL1612203T3 (pl) * 2004-06-28 2007-12-31 Gruenenthal Gmbh Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu
KR100591786B1 (ko) 2004-10-19 2006-06-26 휴먼팜 주식회사 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
EA200702558A1 (ru) 2005-05-20 2008-06-30 Янссен Фармацевтика Н. В. Способ получения производных сульфамида
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103172583A (zh) * 2013-03-07 2013-06-26 深圳市资福药业有限公司 一种制备帕瑞昔布的方法
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
CN114441666B (zh) * 2020-11-05 2024-02-27 成都百裕制药股份有限公司 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
ES2183935T3 (es) * 1995-02-13 2003-04-01 Searle & Co Isoxazoles sustituidos para el tratamiento de la inflamacion.
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
JP3631763B2 (ja) * 1996-08-14 2005-03-23 ジー・ディー・サール・アンド・カンパニー ４―［５―メチル―３―フェニルイソキサゾル―４―イル］ベンゼンスルホンアミドの結晶形
AU2003238668A1 (en) * 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib

Also Published As

Publication number Publication date
LV12274A (lv) 1999-05-20
HUP0400923A2 (hu) 2004-08-30
ZA977314B (en) 1998-08-14
NO990541L (no) 1999-02-05
EE04237B1 (et) 2004-02-16
AP1055A (en) 2002-04-04
GEP20022636B (en) 2002-02-25
SK13699A3 (en) 1999-07-12
BG64259B1 (bg) 2004-07-30
IL128255A0 (en) 1999-11-30
PT920422E (pt) 2003-03-31
ATE228117T1 (de) 2002-12-15
LV12274B (en) 1999-09-20
SI9720059B (sl) 2011-11-30
RS49671B (sr) 2007-11-15
AR009244A1 (es) 2000-04-12
IL161224A0 (en) 2004-09-27
WO1998006708A1 (en) 1998-02-19
NO312461B1 (no) 2002-05-13
SI9720059A (sl) 1999-12-31
HK1023125A1 (en) 2000-09-01
CN1205193C (zh) 2005-06-08
TR199900298T2 (xx) 1999-05-21
TW527350B (en) 2003-04-11
EE9900053A (et) 1999-08-16
EA003754B1 (ru) 2003-08-28
EA199900200A1 (ru) 1999-06-24
EP0920422A1 (de) 1999-06-09
JP2000506542A (ja) 2000-05-30
BG103155A (en) 1999-11-30
YU7499A (sh) 2000-03-21
IS1989B (is) 2005-02-15
CA2264104A1 (en) 1998-02-19
IL128255A (en) 2004-06-20
HUP0400923A3 (en) 2007-11-28
EA200000891A1 (ru) 2001-02-26
OA11298A (en) 2003-10-22
CN1233243A (zh) 1999-10-27
US6441014B2 (en) 2002-08-27
CZ33499A3 (cs) 1999-06-16
ES2188971T3 (es) 2003-07-01
IS4961A (is) 1999-01-29
NZ334132A (en) 2000-06-23
EP0920422B1 (de) 2002-11-20
EP1283203A1 (de) 2003-02-12
AP9901458A0 (en) 1999-03-31
UA52684C2 (uk) 2003-01-15
CZ297679B6 (cs) 2007-03-07
US20010003752A1 (en) 2001-06-14
US7135489B2 (en) 2006-11-14
DE69717281D1 (de) 2003-01-02
PL191313B1 (pl) 2006-04-28
US20030004200A1 (en) 2003-01-02
JP2005015497A (ja) 2005-01-20
DK0920422T3 (da) 2003-03-17
LT99024A (en) 1999-07-26
JP3631763B2 (ja) 2005-03-23
PL331607A1 (en) 1999-08-02
BR9711151A (pt) 1999-08-17
LT4551B (lt) 1999-10-25
KR100383148B1 (ko) 2003-05-09
KR20000029994A (ko) 2000-05-25
SK283558B6 (sk) 2003-09-11
AU4093697A (en) 1998-03-06
EA001472B1 (ru) 2001-04-23
NO990541D0 (no) 1999-02-05
RO120771B1 (ro) 2006-07-28
AU722072B2 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
DE69717281D1 (de) Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid
DE69941116D1 (de) G von gdf-8
ATE239011T1 (de) Neuartige form von s-omeprazol
ATE408607T1 (de) Substituierte benzensulfonamid-derivate als wirkstoff-vorläufer von cox-2 inhibitoren
DE69429359D1 (de) Orale zubereitungen von antimykotika
ID24481A (id) Gastrokinetik monosiklik benzamida dari derivat-3-atau-tersubstitusi 4-(aminometil)-piperidin
NO986024D0 (no) Substituerte 3,5-difenyl-1,2,4-triazoler og deres anvendelse som farmas÷yti
DE69720111T2 (de) Vorläufer von Duftstoffen
DE69713643D1 (de) Na, K und Li Salze von Siloxy-Verbindungen
DK0873308T3 (da) O-Carbamoyl-phenylalaninol-forbindelser og deres farmaceutisk anvendelige salte
DE69802726T2 (de) Abscheidung von Titannitridfilme
DE69806558T2 (de) Stabilisierung von 3-Isothiazolonlösungen
DE59609043D1 (de) Feste Lösungen von 1,4-Diketopyrrolopyrrolen
DE69840875D1 (de) Verwaltung von datenstrukturen
DE69935165D1 (de) Herstellung von polyolefin
DE69733607D1 (de) Herstellung von cycloalkyldiarylphosphinen
DE29720795U1 (de) Nagelschraube
BR9506518A (pt) Derivados de 3-aril-alquenil- 1,2,4-oxadiazol
DE69737529D1 (de) Herstellung von 1-butyl-4-piperidinylmethylamin
DE59709798D1 (de) Feste mischungen von 3-isopropyl-2,1,3-benzthiadiazin-4-on-2,2-dioxidsalzen
EE200400073A (et) 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm ja selle kasutamine
DE29704167U1 (de) Schraubnagel
NO953272L (no) Kombinasjoner av retrovirale inhibitorer
DE29702329U1 (de) Nageldübel
SE9702853D0 (sv) Fasning av mynt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee